Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the commencement of an underwritten public offering of 4,000,000 shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock.

Read more:
Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

Major shareholder announcement

Orphazyme A/SCompany announcement                                                                                       No. 60/2020                                                                                                           Company Registration No. 32266355

See the original post here:
Major shareholder announcement

Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will present in a fireside chat and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference being held on October 6, 2020 at 4:45 p.m. ET.

Go here to read the rest:
Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

STAMFORD, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Originally posted here:
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference

Read the original:
Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference

Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia

SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced support for the Preeclampsia Foundation’s recent call to action advocating for accelerating the development and clinical adoption of biomarker tests for the diagnosis of preeclampsia, a life-threatening hypertensive disorder of pregnancy. The foundation issued its call to action urging the life science community and policy makers to accelerate the development and adoption of biomarker-based testing for preeclampsia.

View post:
Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the closing of its initial public offering of 13,529,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares of common stock, at a public offering price of $18.00 per share. The aggregate gross proceeds to PMV Pharma from the offering were approximately $243.5 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by PMV Pharma. PMV Pharma’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “PMVP.”

Read the original:
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of AllocetraTM in COVID-19 patients in severe/critical condition.

Original post:
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Silencil Reviews – Tinnitus Relief Support Supplement Debuts

View original post here:
Silencil Reviews – Tinnitus Relief Support Supplement Debuts

Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer

Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer

Link:
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer